REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K -October 24, 2023 at 11:14 am EDT

REPLICEL LIFE SCIENCES INC.


CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS





For the six months ended June 30, 2023 and 2022


...

Related Keywords

Vancouver ,British Columbia ,Canada ,Taiwan ,China ,Hong Kong ,United States ,Macau ,Chinese ,Canadian ,Lee Buckler ,David Hall ,Party Transactions ,Bus Partnership ,Venture Exchange ,Trichoscience Innovations Inc ,International Financial Reporting Standards ,Company Options ,Shiseido Company ,China Health Industry Co ,Replicel Life Sciences Inc ,Mainpointe Pharmaceuticals ,International Accounting Standards Board ,Company Stock Option Plan ,Technology Transfer Agreement ,While The Company ,Company Or Replicel ,National Instrument ,Given The Company ,Canadian Dollars ,Interim Financial ,Consolidated Interim Statements ,Cel Life Sciences ,Ontario Business Corporations Act ,Replicel Life Sciences ,Trichoscience Innovations ,Accounting Estimates ,Collaboration Agreement ,Health Industry ,Replicel Injector Product Line ,Interpretations Effective ,Collaborative Agreement ,Greater China ,Mainland China ,Contract Liability ,License Fee ,Share Purchase Agreement ,Distribution Agreement ,Cel Injector Product ,Royalty Participation Agreement ,Chief Technology Officer ,Discounted Market Price ,Aging Skin ,Chronic Tendinosis ,Treatment Androgenic Alopecia ,Replicel Injector Product ,Payback Period ,Issue Date ,Required Redemption Date ,Redemption Price ,Novel Coronavirus ,Canada Emergency Business Account ,Government Grants ,Government Assistance ,Government Grant ,News Release ,Preferred Shares ,Each Warrant ,Stock Option Plans ,Stock Option Plan ,Company Options Issued ,Founders Stock Option Agreements ,Risk Management ,Shiseido Company Limited ,Markets ,